CFDE Data Portal | Search BTNL12P

	Label	Description
	BTNL12P Gene (Entity type)	ENSG00000293512 - butyrophilin like 12, pseudogene
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 14 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE161897 MBNL knockout 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE221329 ERK BRAF inhibition thyroid gland 1 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE60217 adenosine 1 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 11 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

BTNL12P

ENSG00000293512 - butyrophilin like 12, pseudogene

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE146358 dopamine 5 v 2 human dn

A Gene Set from LINCS

GSE233679 nicotinamide 14 v 15 human up

A Gene Set from LINCS

GSE161897 MBNL knockout 2 v 1 human dn

A Gene Set from LINCS

GSE221329 ERK BRAF inhibition thyroid gland 1 v 5 human dn

A Gene Set from LINCS

GSE60217 adenosine 1 v 7 human up

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 1 human up

A Gene Set from LINCS

GSE48812 sulforaphane 11 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.